Naringin attenuates high glucose-induced injuries and inflammation by modulating the leptin-JAK2/STAT3 pathway in H9c2 cardiac cells

Changjun Luo1, Xiao Ke2,3, Si Xiong1, Yun Sun4, Qing Xu4, Wei Zhang5, Yiyan Lei6, Yiqian Ding7, Yulan Zhen7, Jianqiang Feng8, Fei Cheng9, Jingfu Chen9

Abstract

Introduction: Our previous study showed that naringin (NRG) protects cardiomyocytes against high glucose (HG)-induced injuries by inhibiting p38 mitogen-activated protein kinase (MAPK). Leptin induces hypertrophy in rat cardiomyocytes via p38/MAPK activation. The present study aimed to test the hypothesis that leptin-Janus kinase 2 (JAK2)/signal transducers and activators of transcription 3 (STAT3), which are responsible for leptin's functions, are involved in HG-induced injuries and cardioprotective effects of NRG in cardiomyocytes.

Material and methods: H9c2 cells were exposed to HG for 24 h to establish a cardiomyocyte injury model. Cells were pretreated with NRG and other drugs before exposure to HG. Protein expression was measured by western blot analysis. Cell viability was detected by Cell Counting Kit-8 assay. Apoptotic cells were assessed by Hoechst 33258 staining assay. Intracellular reactive oxygen species levels were determined by dichlorofluorescein diacetate staining. Mitochondrial membrane potential was evaluated using JC-1. An enzyme-linked immunosorbent assay was performed to determine the inflammatory cytokines.

Results: NRG significantly attenuated HG-induced increases in leptin and Ob-R expression. Pretreatment with either a leptin antagonist (LA) or NRG markedly ameliorated HG-induced elevation of phosphorylated (p)-JAK2 and p-STAT3, respectively. Pretreatment with NRG, LA, Ob-R antagonist, or AG490 clearly alleviated HG-induced injuries and inflammation.

Submitted: 25 January 2019; Accepted: 7 April 2019
Online publication: 7 May 2019

Arch Med Sci 2021; 17 (5): 1145–1157
DOI: https://doi.org/10.5114/aoms.2019.84854
Copyright © 2019 Termedia & Banach
Introduction

Diabetes-associated vascular complications are associated with increased morbidity and mortality worldwide [1]. Notably, diabetic cardiomyopathy (DCM), which is characterized by left ventricular systolic and/or diastolic dysfunction, is a major diabetic complication. Several mechanisms responsible for the progression of DCM have been proposed, including hyperglycemia-mediated myocardial cytotoxicity [2–5], cardiomyocytes apoptosis [2–5], oxidative stress [2–5], and inflammatory reactions [4, 5]. These pathogenic developments commonly regulate the activation of mitogen-activated protein kinase (MAPK) [2], leptin [3], and nuclear factor-κB (NF-κB) [4] pathways. However, the inhibition of these signaling pathways does not prevent DCM, indicating that other mechanisms might contribute to the development of DCM.

Leptin, secreted by adipocytes and cardiomyocytes [3], has been implicated in the regulation of appetite, feeding-related behaviors, and energy metabolism. Leptin predominantly decreases food intake and increases energy consumption. Accumulating evidence has consistently demonstrated that leptin is involved in the development of atherosclerosis [6–8], systemic inflammation [7, 9], cardiovascular dysfunction [10], cardiomyocyte hypertrophy [11], and cardiomyocyte injury [3]. Leptin exerts effects via the Ob-R and downstream signaling cascades, including extracellular signal-regulated kinase 1/2 (ERK1/2) [12], c-Jun N-terminal kinase/stress-activated protein kinase (JNK) [13], p38 MAPK [3, 14], proprotein convertase subtilisin/kexin type 9 [15], and Janus kinase 2 (JNK)/signal transducer and activator of transcription 3 (STAT3) [16]. Furthermore, in diabetes, leptin binds to the Ob-R to promote diabetes-related cardiovascular complications via p38 MAPK [3] and melanocortin-4 receptor signaling pathway [17]. Previous studies have reported that the JAK2/STAT3 pathway is also involved in hyperglycemia-mediated cardiovascular complications [18–20]. However, the effects and associated mechanisms of the JAK2/STAT3 pathway on hyperglycemia-induced cardiomyocyte injury and inflammation remain unknown. Furthermore, whether leptin plays a key role in hyperglycemia-induced cardiomyocyte injury and inflammation and is dependent on the JAK2/STAT3 pathway is unclear.

Conclusions: This study provides new evidence of the NRG protective effects of H9c2 cells against HG-induced injuries possibly via modulation of the leptin-JAK2/STAT3 pathway.

Key words: naringin, high glucose, injury, inflammation, leptin, JAK2/STAT3 pathway.

Material and methods

Material and agents

NRG, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide (JC-1), dichlorofluorescein diacetate (DCFH-DH) and Hoechst 33258 were obtained from Sigma-Aldrich (St Louis, MO). Leptin antagonist (LA), leptin receptor antagonist (ObRa), and AG490 were purchased from ProSpec (East Brunswick, NJ). A Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies (Kumamoto, Japan). Fetal bovine serum (FBS) and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Gibco BRL (Grand Island, NY). Anti-STAT3, anti-phospho-STAT3, anti-JAK2, anti-phospho-JAK2, anti-leptin, and anti-leptin receptor antibodies were supplied by Cell Signaling Technology (Boston, MA), and horseradish peroxidase (HRP)-conjugated secondary antibody and bicinchoninic acid (BCA) protein assay kits were obtained from the KangChen Bio-tech, Inc. (Shanghai, China). Enhanced chemiluminescence (ECL) solution was purchased from the KeyGen Biotech (Nanjing, China).
Cell culture and treatments

H9c2 cardiac cells were provided by the Sun Yat-sen University Experimental Animal Center (Guangzhou, China). Cells were cultured in DMEM supplemented with 10% FBS under an atmosphere of 5% CO₂ at 37°C, then preconditioned with 80 μM NRG for 2 h before exposure to HG for 24 h. To further determine whether the protective effects of NRG and activation of the leptin-JAK2/STAT3 pathway were mediated by HG, cells were preconditioned with 50 ng/ml LA for 24 h or 25 ng/ml ObRa for 2 h or 10 μM AG490 for 30 min prior to exposure to 35 mM glucose for 24 h, respectively. After the treatments, cells were obtained for the following measurements and evaluations. Measurements of apoptosis, intracellular reactive oxygen species (ROS) generation, and matrix metalloproteinase (MMP) dissipation were performed at a cell density of approximately 1 x 10⁶/ml.

Western blot analysis

Following those treatments, cardiac cells were obtained for western blot analysis. Protein expression was tested as follows. First, cardiac cells were lysed, and proteins were quantified using the BCA kit. Next, loading buffer was added to cytosolic extracts and boiled for 5–10 min, and the same amounts of cytosolic extracts were fractionated and transferred into polyvinylidene difluoride (PVDF) membranes. The PVDF membranes were blocked with fat-free milk, incubated with related antibodies (anti-total [t]-STAT3, detecting all forms of STAT3, 1 : 1000 in dilution, anti-phosphorylated [p]-STAT3, 1 : 1000 in dilution, anti-total [t]-JAK2 : detecting all forms of JAK2, 1 : 1000 in dilution, anti-p-JAK2, 1 : 1000 in dilution, anti-leptin, 1 : 1500 in dilution, anti-leptin receptor, 1 : 1500 in dilution, or anti-GAPDH, 1 : 2000 in dilution) in freshly prepared Tris-buffered saline with Tween-20, and then incubated with secondary antibody (HRP-conjugated goat anti-rabbit antibody). Finally, the immunoreactive signals were visualized by ECL detection. In order to quantify the expression level of each protein, the X-ray films were scanned and calculated using ImageJ 1.47i software (National Institutes of Health, Bethesda, MD). The protein levels of p-STAT3 and p-JAK2 were normalized to t-STAT3 and t-JAK2, respectively; the expression levels of leptin and leptin receptor were normalized to GAPDH. Experiments were carried out in triplicate.

Measurement of cell viability

Cardiac cells were obtained for the evaluation of viability as follows. First, cardiac cells were incubated with CCK-8 solution for 1.5 h. Next, absorbance at 450 nm was analyzed using a microplate reader (Molecular Devices, Sunnyvale, CA), and the mean optical density (OD) of each well in the indicated groups was used to calculate the percentage of cell viability based on the following formula: cell viability (%) = (OD of treatment group/OD of control group) x 100. The experiments were repeated five times.

Measurement of apoptosis

Apoptosis in cardiac cells was measured by Hoechst 33258 staining. The measurement was performed as follows. First, cells were washed with PBS, dried, and fixed with 4% paraformaldehyde. Then, the cells were seeded with Hoechst 33258 (5 mg/ml) at 37 °C, washed again with PBS, and dried. Finally, the cells were observed under a fluorescence microscope (BX50-FLA; Olympus, Tokyo, Japan). The experiments were repeated five times.

Measurement of intracellular ROS generation

Intracellular ROS generation was measured as follows. First, cells were washed with PBS, seeded with DCFH-DA solution (10 μM), and cultured for 30 min. Treated cells were washed again with PBS and dried, and finally, were observed using a fluorescence microscope connected to an imaging system (BX50-FLA, Olympus, Tokyo, Japan). The mean fluorescence intensity (MFI) was tested via Image J 1.47i software. The experiment was repeated five times.

Measurement of MMP

MMP was measured as follows: first, the treated cells were washed with PBS; second, cells were seeded with JC-1 (1 mg/l); third, the cells were washed again with PBS and dried; finally, the cells were observed under a fluorescence microscope connected to an imaging system (BX50-FLA, Olympus). The MFI of JC-1 was analyzed using Imagej 1.47i software. The experiments were repeated five times.

Statistical analysis

All data are shown as the mean ± standard error of the mean (SEM). Differences between groups were analyzed by one-way analysis of variance using SPSS 16.0 software (SPSS Inc., Chicago, IL), followed by the least-significant difference post hoc comparison test. Statistical significance was considered for two-sided p-values less than 0.05.

Results

HG enhanced leptin and ObR expression in cardiac cells

H9c2 cells were treated with HG for different times (3, 6, 9, 12, and 24 h), and as shown in Fig-
Leptin expression began to significantly increase after exposure to HG for 3 h, which reached the maximal level at 9 h (Figures 1 A and B). Similarly, the expression of ObR gradually increased over time, peaking at 12 h (Figures 1 C and D).

HG enhanced p-JAK2/STAT3 expression in cardiac cells

To evaluate the effect of HG on the JAK2/STAT3 pathway in cardiac cells, a time-response study was performed. As shown in Figures 2 A and B, the expression of p-JAK2 began to significantly increase after exposure to HG for 3 h, reaching the maximal level at 24 h. Similarly, p-STAT3 expression gradually elevated and peaked at 24 h (Figures 2 C and D).

HG-induced p-JAK2/p-STAT3 upregulation was blocked by an LA or ObRa

Cardiac cells exposed to HG increased p-JAK2 and p-STAT3 expression levels (Figures 3 A–F). However, upregulation of p-JAK2 and p-STAT3 was markedly blocked by treatment with an LA (Figures 3 A–C) or ObRa for 2 h (Figures 3 D–F) prior to HG exposure.

NRG ameliorated the HG-induced upregulation of leptin, ObR, and p-JAK2/p-STAT3 in cardiac cells

H9c2 cells exposed to HG markedly enhanced the expression of leptin (Figures 4 A and B), ObR (Figures 4 A and C), p-JAK2 (Figures 4 A and D), and p-STAT3 (Figures 4 A and E). However, the increased expression of each of these was significantly reduced by 80 μM NRG.

Figure 1. Expression of leptin and ObR in HG-induced H9c2 cardiac cells. A, B – Leptin expression began to significantly increase after exposure to HG for 6 h, and reached the maximal level at 9 h. C, D – ObR was gradually elevated over time, peaking at 12 h.

Figure 2. Expression levels of both p-JAK2 and p-STAT3 in HG-induced H9c2 cardiac cells. A, B – p-JAK2 began to significantly elevate after exposure to HG for 3 h, reaching the maximal level at 24 h. C, D – p-STAT3 gradually increased, peaking at 24 h.
Naringin attenuates high glucose-induced injuries and inflammation by modulating the leptin-JAK2/STAT3 pathway in H9c2 cardiac cells

NRG and leptin-JAK2/STAT3 pathway inhibitors suppressed cytotoxicity in HG-treated cardiac cells

As shown in Figure 5, treatment of H9c2 cells with HG led to a significant decrease in cell viability. The adverse effects were inhibited by pretreatment with 80 μM NRG. Similarly, pretreatment of the cells with LA for 24 h, ObRa for 2 h, or 10 μM AG490 (an inhibitor of JAK2/STAT3) for 30 min also inhibited HG-induced cytotoxicity.

NRG, LA, ObRa, and AG490 ameliorated apoptosis in HG-treated cardiac cells

Results of Hoechst 33258 nuclear staining showed that HG caused apoptosis (Figure 6 B) when compared to the control group (Figure 6 A). Pretreatment of the cells with 80 μM NRG for 2 h prior to HG exposure considerably alleviated HG-induced cell apoptosis (Figures 6 C and K). Similarly, pretreatment of the cells with LA for 24 h (Figures 6 D and K), ObRa for 2 h (Figures 6 E and K), or AG490 for 30 min (Figures 6 F and K) also markedly reduced apoptosis (Figure 6 K).

NRG, LA, ObRa, and AG490 suppressed oxidative stress in HG-induced cardiac cells

As shown in Figure 7 B and K, the exposure of cardiac cells to HG for 24 h increased intracellular ROS levels when compared to the control group (Figure 7 A). Pretreatment with 80 μM NRG for 2 h prior to exposure to HG markedly mitigated HG-triggered ROS production (Figures 7 C and K). Similarly, pretreatment with LA for 24 h (Figures 7 D and K), ObRa for 2 h (Figures 7 E and K), or AG490 for 30 min (Figures 7 F and K) also diminished the accumulation of ROS.

NRG, LA, ObRa, and AG490 improved MMP dissipation in HG-treated cardiac cells

As shown in Figure 8 B and K, the exposure of H9c2 cells to HG triggered mitochondrial damage, leading to MMP dissipation when compared...
to the control group (Figure 8 A). However, pretreatment with 80 μM NRG for 2 h significantly reduced MMP dissipation (Figures 8 C and K). Similarly, pretreatment with LA for 24 h (Figures 8 D and K), ObRa for 2 h (Figures 8 E and K), or AG490 for 30 min (Figures 8 F and K) significantly diminished MMP dissipation.

NRG, LA, ObRa, and AG490 attenuated the HG-induced production of pro-inflammatory cytokines in HG-treated cardiac cells

As shown in Figure 9, the production of interleukin (IL)-1β (Figure 9 A), IL-10 (Figure 9 B), IL-12 (Figure 9 C), and tumor necrosis factor (TNF)-α (Figure 9 D) was markedly increased in HG-induced H9c2 cells compared with the control group (p < 0.01). However, pretreatment with 80 μM NRG for 2 h before exposure to HG markedly reduced the secretion of IL-1β (Figure 9 A), IL-10 (Figure 9 B), IL-12 (Figure 9 C), and TNF-α (Figure 9 D). Similarly, pretreatment with LA for 24 h, ObRa for 2 h, or AG490 for 30 min prior to exposure to HG also diminished the production of these inflammatory cytokines (Figures 9 A–C).

Discussion

This study revealed several novel findings. First, in H9c2 cardiac cells, the leptin-JAK2/STAT3 signaling pathway is involved in HG-induced cell injuries and associated inflammatory reactions. Second, the JAK2/STAT3 pathway is a downstream signal-
Naringin attenuates high glucose-induced injuries and inflammation by modulating the leptin-JAK2/STAT3 pathway in H9c2 cardiac cells

Third, NRG exerts cardioprotective effects against HG-induced injuries and inflammatory responses, which is consistent with our previous research [2–4]. Finally, the cardioprotective effects of NRG are associated with inhibition of the leptin-JAK2/STAT3 pathway.

Our data showed that the exposure of H9c2 cells to HG markedly induced injuries and inflammatory responses, in line with previous research [2–5]. In addition, these injuries and inflammatory responses were significantly alleviated by LA or ObRa, suggesting that leptin and its receptor were involved in HG-induced injuries and inflammatory responses [3, 24]. However, HG-induced H9c2 cell injuries and inflammation could not be completely suppressed by inhibition of the leptin pathway. These findings indicated that HG-induced H9c2 cell injuries and inflammatory responses are multifactorial and deserve further elucidation.

Notably, the JAK2/STAT3 pathway is widely involved in the survival signaling pathway as well as cell proliferation, differentiation, growth, and apoptosis [25–28]. A recent study has demonstrated that N-acetylcysteine, a ROS scavenger, reduces myocardial ischemia reperfusion injury via upregulation of the JAK2/STAT3 pathway in diabetic animals [29]. In addition, it has been shown that the JAK2/STAT3 pathway mediates cardioprotection in streptozocin-induced type 1 diabetic rats. However, the effects and mechanisms of the JAK2/STAT3 pathway on HG-induced cardiac cell injuries and inflammatory responses remain poorly understood. In order to explore these issues, we first investigated the roles of HG on the activation of the JAK2/STAT3 pathway in H9c2 cells. Our data showed that HG increased p-JAK2/p-STAT3 expression, indicating that HG could activate the JAK2/STAT3 pathway. Our finding reflected those of a previous report [30] but was in contrast to another study [19]. These discrepancies might be due to the different study protocols in terms of the stimulation methods used. Cardiomyocytes were treated with both HG and hypoxia/reoxygenation injury in the previous study versus only HG in the current study. In addition, our data indicated that H9c2 cardiac cells pretreated with AG490 significantly inhibited a variety of HG-stimulated injuries, including apoptosis, cytotoxicity, mitochondrial damage, and oxidative stress. These results suggest that JAK2/STAT3 activation is involved in multiple HG-stimulated injuries. Our results are supported by several recent reports [31–33]. Previous research has found that AG490 exerts anti-inflammatory effects [34, 35]. Zhang et al. found that inhibition of the JAK2/STAT3 pathway was involved in anti-inflammatory effects against septic shock-triggered myocardial injuries [32]. Therefore, we postulated that the JAK2/STAT3 pathway may be associated with myocardial inflammation. In the present study, we further observed the roles of JAK2/STAT3 activation on HG-induced inflammatory responses. Similar to previous reports [4, 5], we found that the exposure of H9c2 cells to HG promoted inflammatory responses, as indicated by the upregulation of inflammatory cytokines including IL-1, IL-12, and TNF-α. However, the increased levels of inflammatory cytokines were decreased by AG490, suggesting that the JAK2/STAT3 pathway is involved in the HG-induced production of these pro-inflammatory factors. These data provide novel evidence to support the notion that activation of the JAK2/STAT3 pathway contributes to HG-induced injuries and inflammation in H9c2 cells.

Figure 5. NRG, LA, ObRa, and AG490 attenuated cytotoxicity in HG-induced H9c2 cardiac cells. H9c2 cells were divided into 10 groups (control group, HG group, HG + NRG group, HG + LA group, HG + ObRa group, HG + AG490 group, NRG group, LA group, ObRa group, AG490 group). Cells were exposed to 35 mmol/l of glucose for 24 h in the absence or presence of pretreatment with 80 μmol/l of NRG for 2 h, 50 ng/ml of LA for 24 h, 25 ng/ml of ObRa for 2 h, or 10 μmol/l of AG490 (an inhibitor of STAT3) for 30 min prior to exposure to HG. Cell viability was detected by CCK-8 assay. HG-induced cell cytotoxicity and a significant decrease in cell viability was suppressed by pretreatment with NRG, LA, ObRa, or AG490. Results are presented as the mean ± SEM (n = 5). *P < 0.01, compared with the control group. ‡P < 0.01, compared with the HG-treated group. #P < 0.05, compared with the control group. LA – leptin antagonist, ObRa – leptin receptor antagonist, AG490 – an inhibitor of JAK2/STAT3 pathway.
**Figure 6.** NRG, LA, ObRa, and AG490 diminished apoptosis in HG-induced H9c2 cardiac cells. A–J – Hoechst 33258 nuclear staining followed by photofluorography to observe cell apoptosis. **A** – Control group (CTL). **B** – H9c2 cardiac cells were exposed to 35 mmol/l of glucose for 24 h. **C** – Cells were pretreated with 80 μmol/l of NRG for 2 h prior to exposure to HG for 24 h. **D** – Cells were pretreated with 50 ng/ml of LA for 24 h prior to exposure to HG. **E** – Cells were pretreated with 25 ng/ml of ObRa for 2 h prior to exposure to HG. **F** – Cells were pretreated with 10 μmol/l of AG490 for 30 min prior to exposure to HG. **G** – Cells were treated with 80 μmol/l of NRG for 2 h. **H** – Cells were treated with 50 ng/ml of LA for 24 h. **I** – Cells were pretreated with 25 ng/ml of ObRa for 2 h. **J** – Cells were pretreated with 10 μmol/l of AG490 for 30 min. **K** – Quantitative analysis of MFI using ImageJ 1.47i software (A–J). 

Data are shown as the mean ± SEM (n = 5). **P < 0.01, compared with the control group. ‡P < 0.01, compared with the HG-treated group. *P < 0.05, compared with the control group. NRG – naringin, LA – leptin antagonist, ObRa – leptin receptor antagonist, AG490 – an inhibitor of JAK2/STAT3 pathway.
Naringin attenuates high glucose-induced injuries and inflammation by modulating the leptin-JAK2/STAT3 pathway in H9c2 cardiac cells

Figure 7. NRG, LA, ObRa, and AG490 decreased ROS production in HG-treated H9c2 cardiac cells. A–J – DCFH-DA staining followed by photofluorography to observe the intracellular ROS level. A – Control group. B – Cells were exposed to 35 mmol/l of glucose for 24 h. C – Cells were pretreated with 80 μmol/l of NRG for 2 h prior to exposure to HG for 24 h. D – Cells were pretreated with 50 ng/ml of LA for 24 h prior to exposure to HG. E – Cells were pretreated with 25 ng/ml of ObRa for 2 h prior to exposure to HG. F – Cells were pretreated with 10 μmol/l of AG490 for 30 min prior to exposure to HG. G – Cells were treated with 80 μmol/l of NRG for 2 h. H – Cells were treated with 50 ng/ml of LA for 24 h. I – Cells were pretreated with 25 ng/ml of ObRa for 2 h. J – Cells were treated with 10 μmol/l of AG490 for 30 min. K – Quantitative analysis of MFI using ImageJ 1.47i software and the data in A–J.

Data are shown as the mean ± SEM (n = 5). *P < 0.01, compared with the control group. †P < 0.01, compared with the HG-treated group. ‡P < 0.05, compared with the control group. NRG – naringin, LA – leptin antagonist, ObRa – leptin receptor antagonist, AG490 – an inhibitor of the JAK2/STAT3 pathway.
Figure 8. NRG, LA, ObRa, and AG490 ameliorated the dissipation of MMP in the HG-treated H9c2 cardiac cells. 
A–J – After the indicated treatment, MMP was assessed by JC-1 staining followed by photofluorography. A – Control group. B – Cells were treated with 35 mmol/l of glucose for 24 h. C – Cells were pretreated with 80 μmol/l of NRG for 2 h prior to exposure to HG for 24 h. D – Cells were pretreated with 50 ng/ml of LA for 24 h prior to exposure to HG. E – Cells were pretreated with 25 ng/ml of ObRa for 2 h before exposure to HG. F – Cells were pretreated with 10 μmol/l of AG490 for 30 min prior to exposure to HG. G – Cells were treated with 80 μmol/l of NRG for 2 h. H – Cells were pretreated with 50 ng/ml of LA for 24 h. I – Cells were pretreated with 25 ng/ml of ObRa for 2 h. J – Cells were pre-treated with 10 μmol/l of AG490 for 30 min. K – Quantitative analysis of the MFI of JC-1 using ImageJ 1.47i software and the data in A–J.

Data are shown as the mean ± SEM (n = 5). *P < 0.01, compared with the control group. †P < 0.01, compared with the HG-treated group. ‡P < 0.05, compared with the control group. NRG – naringin, LA – leptin antagonist, ObRa – leptin receptor antagonist, AG490 – an inhibitor of the JAK2/STAT3 pathway.
Naringin attenuates high glucose-induced injuries and inflammation by modulating the leptin-JAK2/STAT3 pathway in H9c2 cardiac cells

Figure 9. NRG, LA, ObRa, and AG490 suppressed the HG-induced increase in production of pro-inflammatory cytokines in HG-treated H9c2 cardiac cells. H9c2 cells were divided into 10 groups (control group, HG group, HG + NRG group, HG + LA group, HG + ObRa group, HG + AG490 group, NRG group, LA group, ObRa group, and AG490 group). Cells were exposed to 35 mmol/l glucose for 24 h in the absence or presence of pretreatment with 80 μmol/l of NRG for 2 h, 50 ng/ml LA for 24 h, 25 ng/ml of ObRa for 2 h, or 10 μmol/l of AG490 for 30 min prior to exposure to HG. An enzyme-linked immunosorbent assay was performed to determine the levels of IL-1β, IL-10, IL-12, and TNF-α in cell supernatants. A–D – HG-induced increases in IL-1β, IL-10, IL-12, and TNF-α were suppressed by pretreatment with NRG, LA, ObRa, or AG490. Data are presented as the mean ± SEM (n = 5). *P < 0.01, compared with the control group. ‡P < 0.01, compared with the HG-treated group. *P < 0.05, compared with the control group. LA – leptin antagonist, ObRa – leptin receptor antagonist, AG490 – an inhibitor of the JAK2/STAT3 pathway.
A novel finding of our research was the identification of an association between leptin and the JAK2/STAT3 pathway in the HG-induced cardiac cells injury model. A previous paper demonstrated that leptin exerts various physiological functions by activating the JAK2/STAT3 pathway [16]. However, the relationship between leptin and the JAK2/STAT3 pathway is unknown under diabetic conditions. Our study found that the exposure of H9c2 cells to HG increased the expression levels of leptin and ObR and activated the JAK2/STAT3 pathway (up-regulation of p-JAK2 and p-STAT3). We also observed that pretreatment with LA or ObRa markedly suppressed the activation of JAK2/STAT3 (down-regulation of p-JAK2 and p-STAT), indicating that JAK2/STAT3 is a downstream molecular of leptin. Furthermore, pretreatment with LA, ObRa, or AG490 significantly antagonized HG-induced injury and inflammatory responses in H9c2 cells, suggesting that the leptin-JAK2/STAT3 pathway mediated the HG-induced injuries and inflammatory responses in H9c2 cells. However, NRG, LA, ObRa, and AG490 were unable to completely inhibit HG-induced apoptosis, cytotoxicity, mitochondrial damage, or oxidative stress. We are uncertain about the underlying mechanisms. We believe that it will be helpful to evaluate other activating signaling cascades such as ERK1/2, JNK, P38 MAPK, PKC, and NF-κB in future studies to elucidate whether other signaling pathways are also involved.

Another novel finding of this study was that we discovered that the cardioprotective effects of NRG on HG-induced injuries and inflammatory responses were mediated by inhibition of the leptin-JAK2/STAT3 pathway. Our results showed that NRG exerted cardioprotective effects by inhibiting HG-induced injuries and inflammatory responses, which was consistent with our previous reports [2–4]. In addition, NRG inhibited the leptin pathway [3] and JAK2/STAT3 pathway [22]. We further demonstrated the effects of NRG on leptin and JAK2/STAT3 inhibition. Pretreatment with NRG significantly diminished the activation of the leptin pathway (downregulation of the expression levels of leptin and ObR) and JAK2/STAT3 activation (downregulation of p-JAK2 and p-STAT). Our data demonstrated that NRG suppressed the activation of the leptin-JAK2/STAT3 pathway in HG-induced H9c2 cardiac cells. Furthermore, the inhibitory effects of NRG on the leptin-JAK2/STAT3 pathway contributed to the cardioprotective effects against HG-induced H9c2 cells injuries and inflammatory responses.

The limitation of our current study was that we could not demonstrate a causal relationship between the JAK/STAT3 pathway and leptin. However, we considered that the findings from our study might, at least partially, have provided insights into the association between the JAK/STAT3 signaling pathway and leptin in cardiomyocytes. In future studies, the addition of recombinant leptin protein to cardiomyocytes in vitro and measurements of the changes in p-JAK2, p-STAT3, total (t)-JAK2, and t-STAT3 protein expression would demonstrate whether there is a causal relationship between JAK/STAT3 expression and leptin. Moreover, the western blot analysis of p-JAK2 and p-STAT3 did reveal the variations among different sets of the experiments, and the discrepancies may be due to the semi-quantitative method of densitometric analysis as well as the variations in the processing procedures among different sets of western blot analysis. As such, we should be cautious when interpreting our results and further studies may employ the immunohistochemically analysis to consolidate our data in western blot analysis.

In conclusion, this study provides novel evidence that the leptin-JAK2/STAT3 pathway contributes to HG-induced cardiac cell injuries and inflammation and NRG exerts cardioprotective effects against HG-induced cardiac cell injuries and inflammatory responses, and the effects may be related to the modulation of the leptin-JAK2/STAT3 signaling pathway. In line with our current findings, further studies should be conducted to develop and evaluate the novel therapeutic methods for the prevention and treatment of hyperglycemia-associated cardiac cell injuries and inflammation in the future.

Acknowledgments

Changjun Luo, Xiao Ke and Yun Sun equally contributed in this article.

This study was supported by grants from the Science and Technology Project of Shenzhen City, China (Nos.JCYJ20170307161535847 and JCYJ20170413114916687), by a grant from the Samming Project of Medicine in Shenzhen, China (No. SZSM201612048), and by a grant from the Technology Planning Project (201544-01) of Huangpu District, Medical Scientific Research Foundation of Guangdong Province (No. A2015287). The study was supported by grants from the Research Project (Doctoral Innovation Program) of Health Planning System of Shenzhen City (SZBC2017007). The study was supported by Projects of the Provincial Health and Family Planning Commission of Guangxi (NO.Z2016271/Z20170024/Z20170021).

Conflict of interest

The authors declare no conflict of interest.

References

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
2. Chen J, Guo R, Yan H, et al. Naringin inhibits ROS-activated MAPK pathway in high glucose-induced injuries in H9c2 cardiac cells. Basic Clin Pharmacol Toxicol 2014; 114: 293-304.
Naringin attenuates high glucose-induced injuries and inflammation by modulating the leptin-JAK2/STAT3 pathway in H9c2 cardiac cells

3. Chen J, Mo H, Guo R, You Q, Huang R, Wu K. Inhibition of the leptin-induced activation of the p38 MAPK pathway contributes to the protective effects of naringin against high glucose-induced injury in H9c2 cardiac cells. Int J Mol Med 2014; 33: 605-12.

4. You Q, Wu Z, Wu B, et al. Naringin protects cardiomyocytes against hyperglycemia-induced injuries in vitro and in vivo. J Endocrinol 2016; 230: 197-214.

5. Xu W, Chen I, Lin J, et al. Exogenous H2S protects H9c2 cardiac cells against high glucose-induced injury and inflammation by inhibiting the activation of the NF-kappaB and IL-1beta pathways. Int J Mol Med 2015; 35: 177-86.

6. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.

7. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol 2006; 57: S05-28.

8. Dubey L, Hesong Z. Role of leptin in atherogenesis. Exp Clin Cardiol 2006; 11: 269-75.

9. La Cava A, Alviggi C, Matarese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med (Berl) 2004; 82: 4-11.

10. Ren J. Leptin and hyperleptinemia-from friend to foe for metabolic and cardiovascular function. J Endocrinol 2004; 181: 1-10.

11. Majumdar P, Chen S, George B, Sen S, Karmazyn M, Chakrabarti S. Leptin and endothelin-1 mediated increased extracellular matrix protein production and cardiomyocyte hypertrophy in diabetic heart disease. Diabetes Metab Res Rev 2009; 25: 452-63.

12. Ren J, Li X, Zhang J, et al. Leptin induces osteocalcin expression in ATDC5 cells through activation of the MAPK-ERK1/2signaling pathway. Oncotarget 2016; 7: 64021-9.

13. Wang Y, Xu Z, Wang J, Xu S, DUSP19, a downstream effector of leptin, inhibits chondrocyte apoptosis via dephosphorylating JNK during osteoarthritis pathogenesis. Mol Biosyst 2016: 12: 721-8.

14. Xue R, Lei S, Xiao YZ, et al. Selective inhibition of PTEN preserves ischaemic post-conditioning cardioprotection in STZ-induced type 1 diabetic rats: role of the PI3K/Akt and JAK2/STAT3 pathways. Clin Sci (Lond) 2016; 130: 377-92.

15. Liu Z, Lei M, Jiang Y, et al. High glucose attenuates VEGF expression in rat multipotent adult progenitor cells in association with inhibition of JAK2/STAT3 signaling. J Cell Mol Med 2009; 13: 3427-36.

16. Zhang M, Wang X, Wang X, et al. Oxymatrine protects against MHE. Cell Physiol Biochem 2014; 34: 291-303.

17. Zheng D, Cai A, Xu R, et al. Inhibition of JAK2/STAT3-mediated VEGF upregulation under high glucose conditions by PEDF through a mitochondrial ROS pathway in vitro. Invest Ophthalmol Vis Sci 2010; 51: 64-71.

18. Fiaschi T, Magherini F, Gamberi T, et al. Hyperglycemia and angiotensin II cooperate to enhance collagen I deposition and IL-1beta pathways. J Mol Med Sci 2018; 14: 725-34.

19. Hu J, Yang L, et al. The inactivation of JAK2/STAT3 signalling and desensitization of M1 mAChR in minimal hepatic encephalopathy (MHE) and the protection of naringin against MHE. Cell Physiol Biochem 2014; 34: 1933-50.